Yesterday Novo Nordisk said it sued one compounding pharmacy and refiled a lawsuit against another after finding their products claiming to contain the active ingredient for its in-demand weight-loss drug Wegovy were impure, some by as much as 33%.
Boehringer Ingelheim is striking a deal to leverage artificial intelligence for some of the hardest to treat cancers. Phenomic AI announced a collaboration agreement with the pharma giant Wednesday.
Cigna is in merger talks with Humana a source familiar with the matter said on Wednesday, potentially marking the latest in a long string of deals aimed at consolidation of the industry.
In our highly polarized time, the idea that prescription drugs in the U.S. are priced unfairly compared with other countries is a rare issue that draws support from both sides of the aisle.
Under the terms of the deal, Lilly will make an upfront payment and pledges up to $660 million in preclinical, clinical and commercial development milestones. The Japanese biotech will also be eligible for royalties on future sales of any pharmaceutical product that emerges from the partnership.
The clearance is the first ever for an oral appliance, along with a mode of respiratory ventilation or exercise training program for the muscles around face, mouth and tongue, to treat moderate and severe OSA in adults.
Using electronic health records, healthcare analytics firm Truveta contends that Lilly’s Mounjaro (tirzepatide) could achieve stronger and faster weight loss than Novo Nordisk’s Ozempic (semaglutide).
Philips shares fell more than 6% on Wednesday after the U.S. Food and Drug Administration said it is alerting patients of a new safety issue with machines made by the group that are used for the treatment of obstructive sleep apnea.
Avidity will get a $60 million upfront cash payment in addition to BMS scooping up $40 million of its stock to deliver new cardiovascular treatments utilizing the former’s antibody oligonucleotide conjugates.
The updated Novavax shot, which was authorized in the U.S. last month, targets a descendant of the XBB lineage of the coronavirus that was globally predominant earlier this year.
